Enterome, a clinical-stage biopharmaceutical company, will present updated efficacy data from its Phase 1/2 trial of EO2401 in combination with nivolumab +/- bevacizumab for the treatment of recurrent glioblastoma at the Society for Neuro-Oncology (SNO) 28th Annual Meeting. The trial aims to assess the safety, tolerability, immunogenicity, and preliminary efficacy of the combination in 100 patients enrolled at 10 clinical sites in Europe and the US. Enterome is headquartered in Paris, France.
A 13-year-old boy named Lucas from Belgium has become the first known child to be cured of diffuse intrinsic pontine glioma (DIPG), a rare and aggressive form of brain cancer. Lucas underwent treatments for seven years at the Gustave Roussy Cancer Center in Paris, led by Dr. Jacques Grill, and his tumor has completely disappeared. DIPG is a devastating rare brain cancer, with around 300 cases diagnosed in the United States and 100 in France each year. Most children with DIPG survive for less than a year after diagnosis. Lucas participated in a clinical trial in France called BIOMEDE and responded positively to a drug called Everolimus, leading to the total disappearance of his tumor. This outcome is unprecedented globally. Lucas's recovery offers hope for future advancements in treating DIPG and inspires families worldwide affected by this challenging disease.
Longeveron stock (NASDAQ:LGVN) rallies 85% after announcing presentation of Phase 2a CLEARMIND study results for Lomecel-B therapy in treating mild Alzheimer's disease at Alzheimer's Association International Conference. The oral presentation is scheduled for July 28, with a poster presentation on July 30. Topline results were announced in October, with additional data released in December. [0dae3ab5]
Antengene Corporation Limited will present one oral presentation and three poster presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. The oral presentation will focus on a Phase II study of ATG-008, an mTORC1/2 inhibitor, combined with a PD-1 antibody in patients with cervical cancer. The three poster presentations will cover Phase I/II studies of ATG-031 (anti-CD24 monoclonal antibody), ATG-022 (Claudin 18.2 antibody-drug conjugate), and selinexor (XPO1 Inhibitor). The company will also publish a journal article on the results of a Phase I study of ATG-017, an ERK1/2 inhibitor, in patients with advanced solid tumors. The ASCO Annual Meeting will take place from June 1-4, 2024, in Chicago, Illinois. Antengene is a global biopharmaceutical company focused on developing innovative cancer treatments. [9635a87f]